Skip to main content
. 2026 Feb 2;10(2):103374. doi: 10.1016/j.rpth.2026.103374

Figure 2.

Figure 2

Human plasma enhances multidrug-resistant Staphylococcus aureus (MRSA) killing by induced pluripotent stem cell (iPSC)-derived platelets (iPSC-PLTs) via immunoglobulin G. (A) MRSA-killing assay with or without the addition of human plasma for iPSC-PLTs (Sev2) or no platelet (PLT; control) condition. (B) Flow cytometry analysis of CD62P expression, PAC-1 binding, and annexin V binding in Sev2 treated with or without human plasma. (C) MRSA-killing assay using Sev2 pretreated with antihuman CD32 (FcγRIIA) antibody in the absence or presence of human plasma. Compiled data of 5 independent experiments. Data are presented as means ± SEM. ∗P < .05, ∗∗P < .01, ∗∗∗P < .001, ∗∗∗∗P < .0001.